AR121392A1 - Métodos y composiciones para modular los niveles de arginina en células inmunitarias - Google Patents

Métodos y composiciones para modular los niveles de arginina en células inmunitarias

Info

Publication number
AR121392A1
AR121392A1 ARP210100448A ARP210100448A AR121392A1 AR 121392 A1 AR121392 A1 AR 121392A1 AR P210100448 A ARP210100448 A AR P210100448A AR P210100448 A ARP210100448 A AR P210100448A AR 121392 A1 AR121392 A1 AR 121392A1
Authority
AR
Argentina
Prior art keywords
arginine
methods
cells
car
compositions
Prior art date
Application number
ARP210100448A
Other languages
English (en)
Spanish (es)
Inventor
Kwok Ming Cheung
Original Assignee
Sky Perfect International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sky Perfect International Ltd filed Critical Sky Perfect International Ltd
Publication of AR121392A1 publication Critical patent/AR121392A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
ARP210100448A 2020-02-21 2021-02-22 Métodos y composiciones para modular los niveles de arginina en células inmunitarias AR121392A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062979805P 2020-02-21 2020-02-21

Publications (1)

Publication Number Publication Date
AR121392A1 true AR121392A1 (es) 2022-06-01

Family

ID=77390457

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100448A AR121392A1 (es) 2020-02-21 2021-02-22 Métodos y composiciones para modular los niveles de arginina en células inmunitarias

Country Status (13)

Country Link
US (1) US20230265386A1 (cg-RX-API-DMAC7.html)
EP (1) EP4107254A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023515806A (cg-RX-API-DMAC7.html)
KR (1) KR20220157396A (cg-RX-API-DMAC7.html)
CN (1) CN115427553A (cg-RX-API-DMAC7.html)
AR (1) AR121392A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021223138A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016571A2 (cg-RX-API-DMAC7.html)
CA (1) CA3171901A1 (cg-RX-API-DMAC7.html)
IL (1) IL295606A (cg-RX-API-DMAC7.html)
MX (1) MX2022010280A (cg-RX-API-DMAC7.html)
TW (1) TW202144569A (cg-RX-API-DMAC7.html)
WO (1) WO2021164753A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202018554D0 (en) * 2020-11-25 2021-01-06 Cancer Research Tech Ltd Nucleic acid constructs and cells
CN114788870B (zh) * 2022-04-29 2023-06-06 浙江大学 靶向免疫细胞长效补充精氨酸并中和酸环境的组合物及应用
WO2026063691A1 (ko) * 2024-09-20 2026-03-26 삼성바이오에피스 주식회사 아르기니노숙시네이트 합성효소를 암호화하는 코돈-최적화된 폴리뉴클레오티드 및 이를 포함하는 rAAV 생산용 플라스미드

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
EP3525803B1 (en) * 2016-10-13 2022-12-07 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
GB201701332D0 (en) * 2017-01-26 2017-03-15 Tc Biopharm Ltd Immune cells with modified metabolism and their use thereof
GB201721833D0 (en) * 2017-12-22 2018-02-07 Cancer Research Tech Ltd Fusion proteins

Also Published As

Publication number Publication date
IL295606A (en) 2022-10-01
TW202144569A (zh) 2021-12-01
AU2021223138A1 (en) 2022-09-29
US20230265386A1 (en) 2023-08-24
JP2026063215A (ja) 2026-04-10
CA3171901A1 (en) 2021-08-26
EP4107254A1 (en) 2022-12-28
CN115427553A (zh) 2022-12-02
KR20220157396A (ko) 2022-11-29
WO2021164753A1 (en) 2021-08-26
BR112022016571A2 (pt) 2022-11-16
MX2022010280A (es) 2022-11-16
JP2023515806A (ja) 2023-04-14
EP4107254A4 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
MX2022010280A (es) Metodos y composiciones para modular las concentraciones de arginina en celulas inmunitarias.
Xu et al. A metabolism toolbox for CAR T therapy
Módis et al. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part II. Pathophysiological and therapeutic aspects
Nishino Cancer prevention by carotenoids
CL2024000275A1 (es) Composiciones dirigidas al músculo genomodificadas
Li et al. Uptake and protective effects of ergothioneine in human endothelial cells
AR112328A1 (es) Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis
ECSP22056585A (es) Variantes de alfa-glucosidasa ácida diseñadas por ingeniería
Almeida et al. Carbon monoxide improves neuronal differentiation and yield by increasing the functioning and number of mitochondria
US20220105186A1 (en) Compositions Containing Nucleosides and Manganese and Their Uses
Feng et al. Biogenic polyphosphate nanoparticles from Synechococcus sp. PCC 7002 exhibit intestinal protective potential in human intestinal epithelial cells in vitro and murine small intestine ex vivo
MX2024002436A (es) Celulas que expresan il-10 para inmunoterapias mejoradas contra el cancer.
EA202191728A1 (ru) Комбинированная терапия arm и естественными клетками-киллерами
MX2020006808A (es) Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral.
MX2025003457A (es) Elementos para el desdireccionamiento de la expresión génica en el ganglio de la raíz dorsal y/o el hígado
Kim et al. Radioprotective effects of delphinidin on normal human lung cells against proton beam exposure
ES2690545T3 (es) Combinación de EPA, DPA y/o DHA con un agente quimioterapéutico
MX2024002390A (es) Metodos para generar celulas inmunitarias primarias.
MX2025011650A (es) Composiciones, sistemas y métodos para el tratamiento del cáncer mediante campos de tratamiento de tumores y células asesinas
CN102946888B (zh) 含有嘌呤和嘧啶核苷、肽和锰的组合物及其用途
BR112023020861A2 (pt) Materiais e métodos para modificação genética otimizada de células t de memória análogas às células-tronco
Scarpelli et al. Strategies for treating mitochondrial disorders: an update
MX2022006319A (es) Suministro de celulas inmunitarias de sialidasa a celulas cancerosas, celulas inmunitarias y microambiente tumoral.
Tuji et al. Ultrastructural assessment of the radioprotective effects of sodium selenite on parotid glands in rats
Wong et al. Urease-induced alkalinization of extracellular pH and its antitumor activity in human breast and lung cancers.